Gennex Laboratories Limited (531739) Fair Value & Analysis
Healthcare · IN · Market cap ₹473M
Fair value as of: Aug 13, 2026
From 15 valuation models · updated 5 days ago
Below-average quality, screening 132% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (25/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (₹20.86). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹3.63 – ₹27.87 · fair‑value band ₹20.86 – ₹34.77 · the ₹12.00 price screens below the ₹27.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Gennex Laboratories Limited (531739) currently trades at ₹12.00, while our model-based Fair Value estimate is ₹27.82, implying the stock looks roughly 131.8% undervalued today. The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Gennex Laboratories Limited generated revenue of ₹530M at a net margin of 2.7%. Revenue declined 19.7% year over year. Net debt stands at ₹793M. The stock trades on a trailing P/E of 32.2 (as of Jul 4, 2026). Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹20.86 (bear case) to ₹34.77 (bull case); at ₹12.00, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 70% above its 52-week low. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at 132%, 531739 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Growth Earnings (₹46.87) versus Economic Profit (₹9.37). Highest evidence: ROIC Compounder (72).
Notify me when 531739 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 29 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Gennex Laboratories Limited engages in the manufacturing and selling of bulk drugs, intermediates, and biotech products in India and internationally. The company offers active pharmaceutical ingredients, including Guaifenesin; Methocarbamol; Fluconazole; Phenazopyridine Hcl; Allopurinol; and Ketoconazole.
Full company description
Gennex Laboratories Limited engages in the manufacturing and selling of bulk drugs, intermediates, and biotech products in India and internationally. The company offers active pharmaceutical ingredients, including Guaifenesin; Methocarbamol; Fluconazole; Phenazopyridine Hcl; Allopurinol; and Ketoconazole. Its pipeline products include Melitracen Hydrochloride; Flupentixol Di-Hydrochloride; Domperidone; Potassium Guaiacol Sulphonate; Mefenamic Acid; Melitracen; and Chlorphenesin. The company was formerly known as Prudential Pharmaceuticals Limited. Gennex Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Gennex Laboratories Limited reported revenue of ₹1.7B in FY2026 versus ₹612M in FY2022, a compound +29.6%/yr. Reported net income was ₹210M in FY2026, compounding +52.1%/yr from FY2022.
Watch 531739: get an alert when its fair value changes →
Peer Group
Health Care · 2285 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drugs - Generic” was too small, so the broader sector is used.)
Valuation Multiples vs Health Care median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Indoco Remedies Limited 532612 | ₹222.50 | ₹96.79 | -56% |
| Anuh Pharma Limited 506260 | ₹77.18 | ₹51.89 | -33% |
| Gufic Biosciences Limited 509079 | ₹421.20 | ₹182.30 | -57% |
| Medicamen Biotech Limited 531146 | ₹236.75 | ₹95.98 | -59% |
| Mangalam Drugs & Organics Limited 532637 | ₹27.95 | ₹18.52 | -34% |
| Coral Laboratories Limited 524506 | ₹579.05 | ₹779.23 | +35% |
| Lactose (India) Limited 524202 | ₹106.25 | ₹130.91 | +23% |
| Beryl Drugs Limited 524606 | ₹23.18 | ₹14.44 | -38% |
| Novartis AG NVSN | 2,742 MXN | 1,964 MXN | -28% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
Compare Gennex Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Gennex Laboratories Limited (531739) overvalued or undervalued?
What is the fair value of 531739?
What is the quality score of 531739?
What is the revenue of Gennex Laboratories Limited (531739)?
What is the net profit margin of 531739?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Gennex Laboratories Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.